US Stock Insider Trading | Terns disclosed 4 insider trading transactions on February 18

2026-02-20 08:51:20

On February 18, 2026, Terns (TERN) disclosed four insider trading transactions. Director Amy L. Burroughs purchased 14,600 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	4,083	39.80	162,500
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Buy	14,600	4.64	67,700
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	8,159	39.22	320,000
February 18, 2026	Director	Amy L. Burroughs	February 17, 2026	Sell	2,341	38.07	89,100
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Sell	61,200	37.02	2,266,400
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Sell	7,521	37.53	282,200
January 16, 2026	Director	Amy L. Burroughs	January 15, 2026	Buy	68,700	4.64	319,000
January 6, 2026	Executive	Emil Kuriakose	January 2, 2026	Sell	200	39.60	7,920
January 6, 2026	Director	Amy L. Burroughs	January 5, 2026	Sell	71,300	38.10	2,718,200
January 6, 2026	Director	Amy L. Burroughs	January 2, 2026	Buy	21,600	4.64	100,000

[Company Information]

Terns Pharmaceuticals, Inc. was incorporated on December 9, 2016, under the laws of the Cayman Islands. On December 29, 2020, the company deregistered and was domesticated under the Delaware General Corporation Law (by filing a Certificate of Domestication with the Delaware Secretary of State), changing its jurisdiction of incorporation from the Cayman Islands to Delaware. Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing a range of small-molecule candidates to address serious diseases, including oncology and obesity.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes